Rachel Woolstencroft

Large language models enable consensus-level interpretation in metagenomic diagnostics

Eike Steinig, Marcelina Krysiak, Kirti Deo, Andrew Duncan et autres

Abstract Metagenomic sequencing can detect a broad range of pathogens, but interpreting which detections are clinically relevant requires expert adjudication that is difficult to scale and standardize. Here we present diagnostic classifiers that formalize expert adjudication by combining structured decision trees with …

au, gb (code pays fourni par la source)

Vaccination in haematopoietic stem cell transplantation and cellular therapies: consensus, divergence, and uncertainties in global practice

Nalian H. Ibrahim, Sapna Dhunlall, Rachel Woolstencroft, Alice J. Liu et autres

au (code pays fourni par la source)

Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial

Michelle K. Yong, Karin Thursky, Megan Crane, Tim D. Spelman et autres

BACKGROUND: We evaluated whether a daily nasal spray of interferon-alpha (IFN-α) would reduce the incidence of COVID-19 or community-acquired respiratory viral infections in adult cancer patients. METHODS: In this multicenter, randomized, double-blinded, placebo-controlled trial, participants were randomized 1:1 to receive daily 40 …

au (code pays fourni par la source)

Clostridioides difficile infection and recurrence in cancer patients (CIRCA): A multicentre, international study

Pedro Puerta‐Alcalde, Rachel Woolstencroft, Néstor López, Katie Cronin et autres

OBJECTIVES: We aimed to describe the characteristics of Clostridioides difficile infection (CDI) in cancer patients, analysing risk factors for 90-day recurrence and attributable mortality. METHODS: Retrospective analysis on all CDI episodes from 2020 to 2022 in three Australian hospitals and one Spanish …

es, au (code pays fourni par la source)

Interferon-α Nasal Spray to Prevent COVID-19 and Respiratory Viral Infections in Cancer Patients; a Randomised, Double-Blinded Placebo-Controlled Trial

Michelle K. Yong, Karin Thursky, Megan Crane, Tim D. Spelman et autres

au, se (code pays fourni par la source)

Drivers and barriers to COVID-19 vaccination in Australians with cancer

Christie Ann Allan, Amelia Hyatt, Amanda Appathurai, Megan Crane et autres

au (code pays fourni par la source)

Fatal and Nonfatal Events Within 14 days After Early, Intensive Mobilization Poststroke

Julie A Bernhardt, Karen Borschmann, Janice M. Collier, Amanda Gay Thrift et autres

OBJECTIVE: This tertiary analysis from A Very Early Rehabilitation Trial (AVERT) examined fatal and nonfatal serious adverse events (SAEs) at 14 days. METHOD: AVERT was a prospective, parallel group, assessor blinded, randomized international clinical trial comparing mobility training commenced <24 hours poststroke, …

au, gb (code pays fourni par la source)

Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009–2015

Ruth Lynfield, Marcelo Horacio Losso, Richard T. Davey, Alessandro Cozzi‐Lepri et autres

Abstract Background Outcome data from prospective follow-up studies comparing infections with different influenza virus types/subtypes are limited. Methods Demographic, clinical characteristics and follow-up outcomes for adults with laboratory-confirmed influenza A(H1N1)pdm09, A(H3N2), or B virus infections were compared in 2 prospective cohorts enrolled …

au, us, ar, gb, dk (code pays fourni par la source)

Prespecified dose-response analysis for A Very Early Rehabilitation Trial (AVERT)

Julie A Bernhardt, Leonid P. Churilov, Fiona Ellery, Janice Collier et autres

OBJECTIVE: Our prespecified dose-response analyses of A Very Early Rehabilitation Trial (AVERT) aim to provide practical guidance for clinicians on the timing, frequency, and amount of mobilization following acute stroke. METHODS: Eligible patients were aged ≥18 years, had confirmed first (or recurrent) …

au, gb (code pays fourni par la source)

807 IMPACT OF VIRAL LOAD AND CIRRHOSIS ON TREATMENT OUTCOME IN HCV GENOTYPE 3-INFECTED PATIENTS: RESULTS OF THE CANADIAN POWER PROGRAM

P.J. Marotta, Curtis Cooper, Linda J. Scully, David Ka Ki Wong et autres

fr, ca (code pays fourni par la source)